Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ignyta Announces Acquisition of Actagene Oncology and Entry into Oncology Personalized Medicine

Published: Tuesday, May 21, 2013
Last Updated: Tuesday, May 21, 2013
Bookmark and Share
Company adds world class drug discovery and development veterans to management and advisory team.

Ignyta, Inc. announced that it has acquired Actagene Oncology, Inc., effective May 20, 2013. Actagene was a San Diego based privately held biotechnology company founded in February 2013 that was developing personalized medicines for high unmet need cancer indications, based on cancer genome mining and sequencing.

With the acquisition, Ignyta has evolved its business strategy from a sole focus on molecular diagnostics for autoimmune disease to an integrated “Rx/Dx” focus on drug and biomarker discovery and development for cancer and immunology. Patrick O’Connor, Ph.D., CEO of Actagene Oncology, has joined Ignyta as Chief Scientific Officer and SVP, Head of Research. His contributions to the field of oncology include over 100 publications and patents and over 20 compounds brought into development, including the recently approved anticancer drugs Xalkori (Crizotinib) and Inlyta (Axitinib), discovered at Pfizer where Dr. O’Connor served as the Global Research Therapeutic Area Head for Oncology.

Other additions to Ignyta’s management team include Jean-Michel Vernier, Ph.D., who formerly led chemistry groups at Ardea Biosciences, Valeant Pharmaceuticals and Merck Research Laboratories, to serve as VP, Medicinal Chemistry; Paul Pearson, Ph.D., former Global Head and VP, Pharmacokinetics and Drug Metabolism at Amgen, to head PK, Drug Metabolism & Safety; and Dave Matthews, Ph.D., the scientific founder of Agouron Pharmaceuticals, to head Crystallography at Ignyta. James Bristol, Ph.D., former Worldwide Head of Pfizer Discovery and Former Head of Discovery and Chemistry at Warner-Lambert/Parke Davis, at which site Lipitor was discovered by his Chemistry team, joined Ignyta’s Scientific Advisory Board.

“The Actagene acquisition provides Ignyta with a strategic entry into oncology personalized medicine, an area with high unmet medical need and opportunities to give patients customized treatment options that leverage Ignyta’s biomarker discovery capabilities. Ignyta also gains the addition of Patrick O’Connor and the rest of his world class oncology drug hunter team that has collectively discovered and developed 10 approved drugs representing over $5 billion in 2012 sales,” said Jonathan Lim, M.D., chairman and CEO of Ignyta. “Actagene’s R&D team complements Ignyta’s existing team, platform and capabilities, such as whole genome methylation analysis, next generation sequencing, Methylome™ database, and bioinformatics expertise. This transaction reshapes us into a seamless Rx/Dx company pursuing a significant growth area of patient stratification and targeted drug discovery and development for cancer patients.”

Actagene Oncology applies its proprietary Oncolome™ database and technologies such as synthetic lethal screening, x-ray crystallography and structure-based drug design to develop new chemical entities against genetic targets that are enriched in certain cancer populations.

“I am excited for the Actagene team to join forces with the Ignyta team, several of whom I had the pleasure to previously work with when I was at Halozyme,” said Dr. O’Connor. “Actagene’s Oncolome platform will combine synergistically with Ignyta’s Methylome platform to provide both genetic and epigenetic insights from patient tumor samples to identify and pursue personalized medicines against activated genes in cancer. The driving scientific focus for our new company will be the discovery and development of revolutionary new drugs targeting activated genes driving cancer growth and evasion of the immune system.”

In addition to its new focus on targeted therapeutic discovery for cancer, Ignyta will continue to advance its companion diagnostic initiatives to generate epigenetic signatures that are predictive of treatment response for specific drug mechanisms within both autoimmune disease and cancer.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!